With the support of all 15 AHSNs, an innovative non-invasive solution for diagnosing coronary heart disease is now being used by 50+ hospitals across England.
The HeartFlow Fractional Flow Reserve CT (FFRCT) Analysis is the first non-invasive diagnostic tool that aids clinicians in determining, vessel by vessel, both the extent of an artery’s narrowing and the impact that the narrowing has on blood flow.
By non-invasively identifying which patients do and do not need intervention, clinicians can reduce unnecessary downstream non-invasive testing and invasive procedures, reduce healthcare system costs and improve patient outcomes.
The solution has the capacity to transform the way coronary artery disease is diagnosed and treated. Learn more about the technology in this short animation.
HeartFlow is one of the products featured on the Innovation and Technology Payment (ITP) programme, an NHS England initiative delivered in partnership with the AHSN Network, which aims to remove barriers to the spread and adoption of innovative products or technologies and the need for multiple price negotiations. It has also been selected as a Rapid Uptake Product (RUP) through the Accelerated Access Collaborative.
52 NHSE hospitals are now using HeartFlow, marking a seven-fold increase since the AHSNs started supporting its rollout through the ITP, and over 10,000 individual scans have been completed in this time. 46% of eligible trusts adopted HeartFlow in the last 12 months.*
* Figures correct September 2019
Through the Meridian Innovation Health Exchange, West Midlands AHSN (WMAHSN) supported HeartFlow with early engagement with trusts in their region, one of which, Russells Hall Hospital, went on to undertake a trial with the technology and became one of the first hospitals to make HeartFlow available to patients.
WMAHSN facilitated introductions with businesses and specialist clinicians and NHS staff at the Innovation and Technology Payment (ITP) launch event. The ITP is an NHS England initiative delivered in partnership with the AHSN Network, which aims to remove barriers to the spread and adoption of innovative products or technologies (medical devices, digital platforms and technologies).
WMAHSN went on to provide support to HeartFlow through the ITP application process, answering questions and signposting to relevant parties, and in April 2018 HeartFlow was announced as one of the successful ITP products to be featured on the programme.
To find out more, including ‘Plans / timescales for further work’ and ‘Opportunities to get involved’ visit https://www.ahsnnetwork.com/case-study/heartflow-transforming-the-way-coronary-heart-disease-is-diagnosed-and-treated